182 related articles for article (PubMed ID: 33429768)
1. Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
Tocia C; Dumitru IM; Alexandrescu L; Petcu LC; Dumitru E
Medicine (Baltimore); 2021 Jan; 100(1):e24059. PubMed ID: 33429768
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
[TBL] [Abstract][Full Text] [Related]
3. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
4. Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome.
Lee SH; Kim CR; Kim KN
Am J Med Sci; 2019 Jan; 357(1):23-28. PubMed ID: 30611316
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
[TBL] [Abstract][Full Text] [Related]
6. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology.
Dolwani S; Metzner M; Wassell JJ; Yong A; Hawthorne AB
Aliment Pharmacol Ther; 2004 Sep; 20(6):615-21. PubMed ID: 15352909
[TBL] [Abstract][Full Text] [Related]
8. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
Lembo A; Rao SSC; Heimanson Z; Pimentel M
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
10. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.
Schey R; Rao SS
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
12. The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study.
Maconi G; Orlandini L; Asthana AK; Sciurti R; Furfaro F; Bezzio C; de Franchis R
Dig Liver Dis; 2015 Aug; 47(8):646-51. PubMed ID: 26004215
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.
Fodor AA; Pimentel M; Chey WD; Lembo A; Golden PL; Israel RJ; Carroll IM
Gut Microbes; 2019; 10(1):22-33. PubMed ID: 29708822
[TBL] [Abstract][Full Text] [Related]
14. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
[TBL] [Abstract][Full Text] [Related]
15. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
16. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
17. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
[TBL] [Abstract][Full Text] [Related]
18. Increased
Ponziani FR; Scaldaferri F; De Siena M; Mangiola F; Matteo MV; Pecere S; Petito V; Sterbini FP; Lopetuso LR; Masucci L; Cammarota G; Sanguinetti M; Gasbarrini A
Benef Microbes; 2020 Oct; 11(6):519-525. PubMed ID: 32885687
[TBL] [Abstract][Full Text] [Related]
19. Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn's Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study.
Wetwittayakhlang P; Verdon C; Starr M; Hahn GD; Golovics PA; Bessissow T; Afif W; Wild G; Bitton A; Lakatos PL
Turk J Gastroenterol; 2023 Jun; 34(6):603-610. PubMed ID: 37162506
[TBL] [Abstract][Full Text] [Related]
20. Predictors of irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease.
Ahmed M; Pu A; Jencks K; Bishu S; Higgins P; Chey WD; Rao K; Lee A
Neurogastroenterol Motil; 2024 Jun; 36(6):e14809. PubMed ID: 38651743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
